PPAR-γ AGONIST PIOGLITAZONE DECREASES ATHEROSCLEROTIC PLAQUE VULNERABILITY - AN IN VIVO STUDY BY 18F-FDG-PET/CT IN A RABBIT MODEL
Q. Zhao,X. Zhao,M. Zhang
DOI: https://doi.org/10.1016/j.cjca.2014.07.591
IF: 6.614
2014-01-01
Canadian Journal of Cardiology
Abstract:Purpose: We aimed at clarifying the underlying mechanisms of pioglitazone on reducing plaque vulnerability.Methods20 male New Zealand white rabbits were randomly divided into 2 groups: pioglitazone group (group P, n=10) and control group (group C, n=10). Atherosclerosis was induced in all rabbits by intermittent high-cholesterol diet and endothelial denudation. Rabbits in group P received pioglitazone (10 mg∙kg-1∙d-1) in addition to the diet. All survival rabbits at 18wks underwent 2 pharmacological triggering to induce plaque rupture. PET/CT scans were performed at 8wks and 18wks. After pharmacological triggering, all rabbits were euthanatized, and aortic histopathological analysis and correlation analysis were performed.ResultsSUVmean and SUVmax at 18wks were respectively 0.492±0.116 and 0.612±0.082, significantly lower than those obtained at 8wks (0.665±0.076 and 0.850±0.072, p=0.020 and 0.004, respectively), in group P. Whereas SUVmean and SUVmax were significantly increased in group C from 8wks (0.800±0.084 and 0.997±0.065) to 18wks (1.033±0.621 and 1.335±0.113, p=0.004 and 0.005, respectively). At the end-stage imaging showed an obviously higher SUVmean and SUVmax in group C (p<0.001 and 0.001, respectively) with respect to group.P. Serum MMP-9 was lower in group P at 8wks (p=0.040) and 18wks (p=0.010) than that in group C. Histopathological examination demonstrated that the percentage of segments (1.5 cm length) with plaque rupture and thrombosis in group P was significantly lower than that in group C (11/75 and 20/51, respectively, χ2=9.862, p=0.002). Morphological assay showed plaque area was quite smaller in group P than in group C (0.029±0.018 vs. 0.186±0.093,p=0.033). Macrophages (8.800±3.936 vs. 30.130±4.188, p=0.003) and neovessels (80.267±13.094 vs. 162.637±73.112, p=0.022) were also markedly reduced in group P compared with group C. Strong positive correlations between SUVmean and plaque area, SUVmax and plaque area, SUVmean and macrophages, and between SUVmax and macrophages were observed (r=0.863,p=0.000; r=0.793,p=0.000; r=0.564,p=0.001 and r=0.550,p=0.001, respectively), whereas no correlations between SUVmean and neovessels or between SUVmax and neovessels (r=-0.081,p=0.687 and r=-0.156,p=0.438) were detected.ConclusionPioglitazone can attenuate plaque vulnerability and decrease the incidence of plaque rupture by ways of modulating vascular inflammation and inhibiting atherosclerosis progression.BNSF Purpose: We aimed at clarifying the underlying mechanisms of pioglitazone on reducing plaque vulnerability. Methods20 male New Zealand white rabbits were randomly divided into 2 groups: pioglitazone group (group P, n=10) and control group (group C, n=10). Atherosclerosis was induced in all rabbits by intermittent high-cholesterol diet and endothelial denudation. Rabbits in group P received pioglitazone (10 mg∙kg-1∙d-1) in addition to the diet. All survival rabbits at 18wks underwent 2 pharmacological triggering to induce plaque rupture. PET/CT scans were performed at 8wks and 18wks. After pharmacological triggering, all rabbits were euthanatized, and aortic histopathological analysis and correlation analysis were performed. 20 male New Zealand white rabbits were randomly divided into 2 groups: pioglitazone group (group P, n=10) and control group (group C, n=10). Atherosclerosis was induced in all rabbits by intermittent high-cholesterol diet and endothelial denudation. Rabbits in group P received pioglitazone (10 mg∙kg-1∙d-1) in addition to the diet. All survival rabbits at 18wks underwent 2 pharmacological triggering to induce plaque rupture. PET/CT scans were performed at 8wks and 18wks. After pharmacological triggering, all rabbits were euthanatized, and aortic histopathological analysis and correlation analysis were performed. ResultsSUVmean and SUVmax at 18wks were respectively 0.492±0.116 and 0.612±0.082, significantly lower than those obtained at 8wks (0.665±0.076 and 0.850±0.072, p=0.020 and 0.004, respectively), in group P. Whereas SUVmean and SUVmax were significantly increased in group C from 8wks (0.800±0.084 and 0.997±0.065) to 18wks (1.033±0.621 and 1.335±0.113, p=0.004 and 0.005, respectively). At the end-stage imaging showed an obviously higher SUVmean and SUVmax in group C (p<0.001 and 0.001, respectively) with respect to group.P. Serum MMP-9 was lower in group P at 8wks (p=0.040) and 18wks (p=0.010) than that in group C. Histopathological examination demonstrated that the percentage of segments (1.5 cm length) with plaque rupture and thrombosis in group P was significantly lower than that in group C (11/75 and 20/51, respectively, χ2=9.862, p=0.002). Morphological assay showed plaque area was quite smaller in group P than in group C (0.029±0.018 vs. 0.186±0.093,p=0.033). Macrophages (8.800±3.936 vs. 30.130±4.188, p=0.003) and neovessels (80.267±13.094 vs. 162.637±73.112, p=0.022) were also markedly reduced in group P compared with group C. Strong positive correlations between SUVmean and plaque area, SUVmax and plaque area, SUVmean and macrophages, and between SUVmax and macrophages were observed (r=0.863,p=0.000; r=0.793,p=0.000; r=0.564,p=0.001 and r=0.550,p=0.001, respectively), whereas no correlations between SUVmean and neovessels or between SUVmax and neovessels (r=-0.081,p=0.687 and r=-0.156,p=0.438) were detected. SUVmean and SUVmax at 18wks were respectively 0.492±0.116 and 0.612±0.082, significantly lower than those obtained at 8wks (0.665±0.076 and 0.850±0.072, p=0.020 and 0.004, respectively), in group P. Whereas SUVmean and SUVmax were significantly increased in group C from 8wks (0.800±0.084 and 0.997±0.065) to 18wks (1.033±0.621 and 1.335±0.113, p=0.004 and 0.005, respectively). At the end-stage imaging showed an obviously higher SUVmean and SUVmax in group C (p<0.001 and 0.001, respectively) with respect to group.P. Serum MMP-9 was lower in group P at 8wks (p=0.040) and 18wks (p=0.010) than that in group C. Histopathological examination demonstrated that the percentage of segments (1.5 cm length) with plaque rupture and thrombosis in group P was significantly lower than that in group C (11/75 and 20/51, respectively, χ2=9.862, p=0.002). Morphological assay showed plaque area was quite smaller in group P than in group C (0.029±0.018 vs. 0.186±0.093,p=0.033). Macrophages (8.800±3.936 vs. 30.130±4.188, p=0.003) and neovessels (80.267±13.094 vs. 162.637±73.112, p=0.022) were also markedly reduced in group P compared with group C. Strong positive correlations between SUVmean and plaque area, SUVmax and plaque area, SUVmean and macrophages, and between SUVmax and macrophages were observed (r=0.863,p=0.000; r=0.793,p=0.000; r=0.564,p=0.001 and r=0.550,p=0.001, respectively), whereas no correlations between SUVmean and neovessels or between SUVmax and neovessels (r=-0.081,p=0.687 and r=-0.156,p=0.438) were detected. ConclusionPioglitazone can attenuate plaque vulnerability and decrease the incidence of plaque rupture by ways of modulating vascular inflammation and inhibiting atherosclerosis progression.BNSF Pioglitazone can attenuate plaque vulnerability and decrease the incidence of plaque rupture by ways of modulating vascular inflammation and inhibiting atherosclerosis progression.